Erin Dennis, MD
Pediatrics · High Point, NCNPI 1588195150
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 399 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AstraZeneca at 25.6% of the total. 2025 is the largest year on record at $3,009, more than ten times the $83 reported in 2020. Among pediatrics clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$992
- Amgen$872
- GSK$779
- Novartis$546
- plus $2K from 28 others
What the payments were for
- Food & beverage$9,09298%
- Education$1732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 91 | $2,374 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,224 |
| Sanofi | 43 | $992 |
| Amgen | 40 | $872 |
| GSK | 45 | $779 |
| Novartis | 28 | $546 |
| AbbVie | 14 | $453 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $301 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $238 |
| Biocryst US Sales Co., LLC | 9 | $218 |
| Genentech USA, Inc. | 9 | $187 |
| Pfizer | 3 | $151 |
| Galderma Laboratories, L.p. | 6 | $105 |
| Octapharma USA, Inc. | 6 | $104 |
| Regeneron | 3 | $102 |
| LEO Pharma Inc. | 6 | $101 |
| Mylan Specialty L.p. | 3 | $66 |
| CSL Behring | 2 | $48 |
| Organon | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Pharming Healthcare, Inc. | 2 | $36 |
| Optinose US, Inc. | 2 | $32 |
| Viatris Specialty LLC | 2 | $28 |
| Aytu Biopharma, Inc. | 2 | $28 |
| Jubilant Hollisterstier LLC | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
| Alk-abello, Inc | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Hospira, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,264 in reported general payments places this provider in the 95th percentile of 1,818 pediatrics providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 49 | $207,216 |
| Dupixent SyringeDupilumab | 27 | $132,564 |
| XolairOmalizumab | 22 | $105,216 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $18,508 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,318 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $12,089 |
| Arnuity ElliptaFluticasone Furoate | 41 | $10,795 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,087 |
| DuleraMometasone/Formoterol | 15 | $7,945 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,943 |
| Epinephrine | 41 | $5,950 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,942 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $3,055 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $3,019 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $2,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $2,374 | $237,813110 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $779 | $37,20077 claims |
| Boehringer IngelheimSpiriva Respimat | $19 | $6,94313 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $5,95041 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $38 | $3,01914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,818 pediatrics providers in North Carolina.
Other pediatrics in High Point
- James AndersonHigh Point$669K
- Dwight KoeberlDurham$8.4M
- Priya KishnaniDurham$5.8M
- Joseph MuenzerChapel Hill$237K
- Ifeyinwa OsunkwoCharlotte$218K
- Edward SmithDurham$164K
- Katherine SmithRaleigh$133K
- James StillRaleigh$105K
- Richard BrugmanGastonia$73K
- Daniel LandiDurham$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.